Triple‑negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 receptors, which limits targeted therapy options and contributes to poor prognosis. Ferroptosis — an iron‑dependent regulated cell death process driven by lipid peroxidation — has emerged as a therapeutic strategy of interest in TNBC because it exploits vulnerabilities in tumor redox homeostasis. Glutathione peroxidase 4 (GPX4) is a principal cellular suppressor of ferroptosis; inhibiting GPX4 promotes accumulation of lipid peroxides and can trigger ferroptotic death in susceptible cancer cells.
DA‑5 is reported as a novel small molecule inspired by natural compounds present in the traditional Chinese medicine Shuganning injection (SGNI). The compound belongs to a class of 3,5‑disubstituted azaindole derivatives and was developed to target GPX4 and induce ferroptosis selectively in TNBC cells.
The study used molecular docking and iterative structural optimization to design DA‑5 with the aim of achieving high‑affinity interaction with GPX4 and functional inhibition of its enzymatic activity. Details of individual docking poses and specific synthetic routes were reported in the original article (full text link available), and the reported design strategy prioritized chemical motifs compatible with GPX4 binding and drug‑like properties suitable for oral administration.
Biophysical and biochemical assays quantified DA‑5 interaction with GPX4. DA‑5 demonstrated measurable binding affinity to GPX4 with a dissociation constant reported as Kd = 10.04 μM. Enzymatic inhibition of GPX4 by DA‑5 was also reported with an inhibitory concentration IC50 = 10.90 μM, indicating that DA‑5 can directly impair GPX4 catalytic activity at low‑to‑mid micromolar concentrations.
In cell‑based assays using TNBC cell lines, DA‑5 treatment led to increased lipid peroxidation, consistent with activation of ferroptotic processes downstream of GPX4 inhibition. The observed cell death phenotype and biochemical markers aligned with ferroptosis rather than other forms of regulated cell death, supporting the intended mechanism of action.
Mechanistic specificity was supported by rescue experiments: co‑treatment with established ferroptosis inhibitors and with iron chelators reversed DA‑5‑induced cell death, indicating that DA‑5 cytotoxicity is dependent on iron and lipid peroxidation pathways characteristic of ferroptosis.
The authors report that DA‑5 induced ferroptosis in TNBC cells while relatively sparing normal mammary epithelial cells in vitro. This selectivity suggests a therapeutic window in which tumor cells with ferroptosis susceptibility are preferentially targeted; however, detailed comparative potency values across cell types were presented in the full text and are not reproduced here beyond the qualitative finding.
DA‑5 was evaluated in vivo using TNBC xenograft models. Oral administration of DA‑5 significantly inhibited tumor growth in these models. The report states that antitumor activity was achieved without systemic toxicity as assessed by the study's safety measures. Specific dosing regimens, tumor growth inhibition metrics, and animal numbers are reported in the full article.
Pharmacokinetic analyses indicated favorable properties for DA‑5 consistent with oral dosing. The authors also report a favorable safety profile in the xenograft studies, with no systemic toxicity observed under the conditions tested. Detailed pharmacokinetic parameters (for example, Cmax, Tmax, half‑life, or bioavailability) and full toxicology findings are provided in the original publication.
The work identifies DA‑5 as a novel azaindole‑based GPX4 inhibitor that induces ferroptosis via GPX4‑targeted lipid peroxidation in TNBC models. DA‑5 shows biochemical GPX4 inhibition (Kd = 10.04 μM; IC50 = 10.90 μM), induces ferroptotic cell death in TNBC cell lines (rescuable by ferroptosis inhibitors and iron chelators), and demonstrates oral antitumor efficacy in xenograft models without observed systemic toxicity. These findings support further investigation of DA‑5 as a targeted therapeutic candidate for TNBC, including more extensive pharmacokinetic, safety, and efficacy studies.
The authors declared that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.